Hsbc Holdings PLC Boosts Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Hsbc Holdings PLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 33.4% in the second quarter, according to its most recent filing with the SEC. The fund owned 81,748 shares of the biopharmaceutical company’s stock after acquiring an additional 20,483 shares during the period. Hsbc Holdings PLC owned approximately 0.06% of Alnylam Pharmaceuticals worth $26,627,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Alnylam Pharmaceuticals by 1.8% during the second quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock worth $4,336,064,000 after purchasing an additional 240,534 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock valued at $1,192,988,000 after buying an additional 33,696 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after buying an additional 185,783 shares in the last quarter. Geode Capital Management LLC lifted its position in Alnylam Pharmaceuticals by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after buying an additional 75,936 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in Alnylam Pharmaceuticals by 1.9% in the second quarter. American Century Companies Inc. now owns 1,793,846 shares of the biopharmaceutical company’s stock worth $584,957,000 after buying an additional 33,411 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 3,821 shares of the firm’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the sale, the executive vice president owned 54,052 shares of the company’s stock, valued at $24,434,206.60. This trade represents a 6.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Pushkal Garg sold 3,022 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the completion of the sale, the executive vice president owned 20,221 shares in the company, valued at approximately $9,129,377.08. This trade represents a 13.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 78,328 shares of company stock valued at $35,705,793 over the last 90 days. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.7%

ALNY opened at $454.32 on Tuesday. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The business has a 50 day simple moving average of $455.72 and a two-hundred day simple moving average of $398.86. The firm has a market capitalization of $60.02 billion, a price-to-earnings ratio of -183.94 and a beta of 0.30.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group lowered their price objective on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a report on Thursday, October 30th. Morgan Stanley upped their price target on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research report on Monday, October 6th. BMO Capital Markets lifted their price objective on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Bank of America increased their target price on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Finally, Citigroup lifted their price target on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Twenty-three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $482.17.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.